The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...
Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.
The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.
The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.
The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.